As of June 30, 2008, NDT Pharmaceuticals Inc. has 42,350.00 shares outstanding.
| Shares Outstanding | 42,350.00 |
As of June 30, 2008, NDT Pharmaceuticals Inc. maintains a current ratio of - -, meaning it holds the short-term assets needed to cover near-term liabilities.
| Debt / Equity | -89.93 |
| Debt / EBITDA | -0.14 |
These figures cover the twelve months ended June 30, 2008. Return on assets (ROA) is negative at -55,756.14, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -55,756.14 |
As of the close on November 16, 2026, NDT Pharmaceuticals Inc.'s stock has declined approximately 89.24% over the past 52 weeks. The 50-day moving average sits at 0.32, while the 200-day moving average is 0.77.
| 52-Week Price Change | -89.24% |
| 50-Day Moving Average | 0.32 |
| 200-Day Moving Average | 0.77 |
These figures cover the twelve months ended June 30, 2008. EBITDA reached -1.09M, while operating income came in at -93,469.00.
| Operating Income | -93,469.00 |
| Net Income | -1.23M |
| EBITDA | -1.09M |
| EBIT | -1.09M |
| Earnings Per Share (EPS) | -29.58 |
As of June 30, 2008, NDT Pharmaceuticals Inc. holds - - in cash and equivalents against 158,284.00 in total debt, resulting in a net debt position of 158,284.00. Total book value stands at -176,005.00, with working capital of -176,005.00 providing operational flexibility.
| Total Debt | 158,284.00 |
| Net Debt | 158,284.00 |
| Equity (Book Value) | -176,005.00 |
| Book Value Per Share | -4.16 |
| Working Capital | -176,005.00 |
NDT Pharmaceuticals Inc. produced -83,796.00 in operating cash flow over the twelve months ended June 30, 2008.
| Operating Cash Flow | -83,796.00 |
| Free Cash Flow | -83,796.00 |
| FCF Per Share | -2.02 |
NDT Pharmaceuticals Inc.'s most recent stock split took place on May 29, 2020 with a 1000:1 split ratio.
| Last Split Date | 5/29/2020 |
| Split Ratio | 1000:1 |